title: Recurrent early pregnancy loss and antiphospholipid antibodies: where do we stand?
abstract: Evidence from basic science studies supports a causative relationship between antiphospholipid antibodies (aPL) and recurrent early miscarriage (REM) (prior to 10 weeks of gestation). However, human studies have not consistently found a relationship between aPL and REM. Members of the Obstetric Task Force of the 14th International Congress on Antiphospholipid Antibodies performed a literature review of the association of aPL and REM and searched for clinical trials in women with REM who tested positive for aPL. Of the 46 studies that investigated the relationship between aPL and REM, 27 found a positive association, seven found no association, and the remaining 12 papers could not report an association (lack of control group). The main identified problems for such conflicting results were varying definitions of REM (two or three abortions, not necessarily consecutive; different gestational age at which pregnancy losses occurred); analysis of patients with previous fetal death (>10 weeks) in the same group of REM; and different definitions of "positive aPL" (cutoffs not following international recommendations; small number of studies confirmed persistence of positive aPL after six to 12 weeks). The 10 identified randomized trials with proposed treatments for women with REM who test positive for aPL also had heterogeneous inclusion criteria, with only one trial limited to subjects who would meet the current criteria for antiphospholipid syndrome (APS) by both clinical and laboratory criteria. Against this background, we conclude that the association between REM and aPL remains inconclusive and that the findings of treatment trials are at best inconsistent and at worst misleading. More convincing data are critically needed. Studies that identify, or at least stratify, according to international consensus criteria and include standardized core laboratory testing results are crucial if we are to establish an evidence-based association between aPL and REM and treatment recommendations.
authors.affiliation: Department of Obstetrics and Gynecology, University of Utah, USA Intermountain Healthcare, USA luchin.wong@hsc.utah.edu.
authors.forename: L F
authors.initials: LF
authors.lastname: Wong
authors.affiliation: Department of Obstetrics and Gynecology, University of Utah, USA Intermountain Healthcare, USA.
authors.forename: T F
authors.initials: TF
authors.lastname: Porter
authors.affiliation: Department of Obstetrics, Universidade do Estado do Rio de Janeiro, Brazil.
authors.forename: G R
authors.initials: GR
authors.lastname: de Jesús
mesh_terms: D000026:Abortion, Habitual / Q000209:etiology* / Q000276:immunology; D017152:Antibodies, Antiphospholipid / Q000097:blood*; D016736:Antiphospholipid Syndrome / Q000150:complications; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D011247:Pregnancy
chemical_list: D017152:Antibodies, Antiphospholipid
keywords: Antiphospholipid syndrome; abortion; antiphospholipid antibodies; aspirin; heparin; pregnancy loss